Scientific sections

**ACB**
Anatomy / Cell Biology

**COS**
Cornea / Ocular Surface

**EOVS**
Electrophysiology, Physiological Optics, Vision Sciences

**G**
Glaucoma

**IM**
Immunology / Microbiology

**LC**
Lens and Cataract

**MBGE**
Molecular Biology / Genetics / Epidemiology

**NSPH**
Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology

**PO**
Pathology / Oncology

**PBP**
Physiology / Biochemistry / Pharmacology

**RV**
Retina / Vitreous Section programme secretaries
EVER 2021 INDUSTRY WEBINAR - 27 SEPTEMBER

21.00-22.00

see pag. 9

EVER 2021 VIRTUAL CONGRESS - 2 OCTOBER

09.30-10.25  Session 1

Moderator: Dominique Bremond-Gignac, France

09.30  ACB  Surgical aspects of RPE cell therapy for AMD
        Boris V. Stanzel, Germany

09.40  COS  Advances and Innovations in Eye Banking and Tissue
        Processing for Corneal Transplantation
        Zisis Gatzioufas, Switzerland

09.50  EOVS  Contribution of adaptive optics ophthalmoscopy to the
           investigation of the Stiles-Crawford effect in retinal
           diseases
           Michel Paques, France

10.00  G  Gene therapy for optic nerve protection and repair
        Keith Martin, Australia

10.10  LIVE Q & A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 2</th>
<th>Time</th>
<th>Session 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30</td>
<td><strong>IM</strong> Cutting-edge imaging for Uveitis Francesco Pichi, Italy</td>
<td>11.30</td>
<td><strong>PO</strong> MR Imaging of Uveal Melanoma with Clinicopathological Correlations Teresa Ferreira, Netherlands</td>
</tr>
<tr>
<td>10.40</td>
<td><strong>LC</strong> Corneal Regeneration: Is it possible? Jorge Alio, Spain</td>
<td>11.40</td>
<td><strong>PBV</strong> Retinal energy metabolism in vascular and avascular retinas Glyn Chidlow, United States</td>
</tr>
<tr>
<td>10.50</td>
<td><strong>MBGE</strong> MicroRNA-mRNA genetic networks in refractive eye development and myopia Andrei V. Tkatchenko, United States</td>
<td>11.50</td>
<td><strong>RV</strong> Venous Overload Choroidopathy: Associated Conditions Richard F. Spaide, United States</td>
</tr>
<tr>
<td>11.00</td>
<td><strong>NSPH</strong> Optic Neuritis and Anti-What?: The NMO and MOG story John J. Chen, United States</td>
<td>12.00</td>
<td><strong>LIVE Q &amp; A</strong></td>
</tr>
</tbody>
</table>

**10.30-11.25 Session 2**

Moderator: **Manuel Vidal-Sanz**, Spain

10.30 **IM** Cutting-edge imaging for Uveitis Francesco Pichi, Italy

10.40 **LC** Corneal Regeneration: Is it possible? Jorge Alio, Spain

10.50 **MBGE** MicroRNA-mRNA genetic networks in refractive eye development and myopia Andrei V. Tkatchenko, United States

11.00 **NSPH** Optic Neuritis and Anti-What?: The NMO and MOG story John J. Chen, United States

11.10 **LIVE Q & A**

**11.30-12.15 Session 3**

Moderator: **Frédéric Mouriaux**, France

11.30 **PO** MR Imaging of Uveal Melanoma with Clinicopathological Correlations Teresa Ferreira, Netherlands

11.40 **PBV** Retinal energy metabolism in vascular and avascular retinas Glyn Chidlow, United States

11.50 **RV** Venous Overload Choroidopathy: Associated Conditions Richard F. Spaide, United States

12.00 **LIVE Q & A**

**12.15-13.00 Industry Lunch Symposium** see pag. 10

**13.00-13.45 Industry Lunch Symposium** see pag. 10
14.00 **ACB**  Phloretin reduced the secretion of IL-8 in retinal pigment epithelial cells suffering from mitochondrial dysfunction via activation of nuclear factor erythroid 2 related factor 2 (NFE2L2/Nrf2)

*Maria Hytti*, Finland

14.05 **COS**  A unique pre-endothelial layer at the posterior peripheral cornea: Ultra-structural study

*Saeed Akhtar*, Saudi Arabia

14.10 **EOVS**  Neuronal sources of visually evoked potentials using selective color opponent channel stimulation

*Sascha Klee*, Germany

14.15 **G**  Multivariate normative comparison, a novel method for improved use of the retinal nerve fiber layer thickness to detect early glaucoma

*Jacqueline Chua*, Singapore

14.20 **IM**  Vision-related quality of life in spondyloarthritis patients with history of acute anterior uveitis under treatment with golimumab: preliminary results of the GO-VISION observational study

*Ines Leal*, Portugal

14.25 **LC**  A comparative study of difluprednate 0.05% Nanoemulsion vs prednisolone acetate 1% + phenylephrine 0.12% Suspension on postoperative inflammation treatment following cataract surgery

*Melina Sol del Papa*, Argentina

14.30 **LIVE Q & A**
14.50-15.30 Session 5 - Rapid Fire

Moderators: Manuel Vidal-Sanz, Spain, Roy Andrew Quinlan, United Kingdom

14.50 MBGE Pharmacogenetics. Phenotype And Genotype Response To Prostaglandin Analogues And Beta Bloquers In A Population Of Glaucoma Patients
Valeria Opazo Toro, Spain

14.55 NSPH Retina Analysis With Optical Coherence Tomography In Patients With Fibromyalgia
Beatriz Cordón Ciordia, Spain

15.00 PO The effects of visible and blue light exposure on growth and melanogenesis of ocular melanoma cell lines
Chieh-Lin (Stanley) Wu, Australia

15.05 PBV Ten differentially expressed proteins in the tear film of dogs with diabetic retinopathy
Dagmara Winiarczyk, Poland

15.10 RV Comparison of quantitative self-monitoring metamorphopsia measurements tools in myopic choroidal neovascularization (mCNV)
Katja Hatz, Switzerland

15.15 LIVE Q & A
### Session 6 - Young Investigators

**Moderators:** João Barbosa Breda, Portugal, Francesca Cordeiro, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15.35</strong></td>
<td>ACB</td>
<td>Effect of systemic immunosupression and BM-MSC allotransplantation in retinal functionality and RGC population&lt;br&gt;&lt;strong&gt;María Norte Muñoz&lt;/strong&gt;, Spain</td>
</tr>
<tr>
<td><strong>15.40</strong></td>
<td>COS</td>
<td>Dendritic cell depletion modifies corneal nerve activity and mice nociceptive behaviour&lt;br&gt;&lt;strong&gt;Laura Rincon Frutos&lt;/strong&gt;, Spain</td>
</tr>
<tr>
<td><strong>15.45</strong></td>
<td>EOV S</td>
<td>Evaluation of the effect of eye movements on the Sweep VEP&lt;br&gt;&lt;strong&gt;Ioannis Dimopoulos&lt;/strong&gt;, Canada</td>
</tr>
<tr>
<td><strong>15.50</strong></td>
<td>G</td>
<td>Glaucoma clinical research: Trends in treatment strategies and drug discovery&lt;br&gt;&lt;strong&gt;Josefine Clement Freiberg&lt;/strong&gt;, Denmark</td>
</tr>
<tr>
<td><strong>15.55</strong></td>
<td>IM</td>
<td>Cytokine profile in tear and aqueous humor of primary open-angle glaucoma patients as a prognostic factor for trabeculectomy outcome&lt;br&gt;&lt;strong&gt;Barbara Burgos-Blasco&lt;/strong&gt;, Spain</td>
</tr>
<tr>
<td><strong>16.00</strong></td>
<td>LC</td>
<td>Spontaneous Lens Subluxation Into Anterior Chamber. Importance Of An Early Management&lt;br&gt;&lt;strong&gt;Ismael Bakkali El Bakkali&lt;/strong&gt;, Spain</td>
</tr>
<tr>
<td><strong>16.05</strong></td>
<td>LIVE Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>
### Session 7 - Young Investigators

**Moderator:** Dominique Bremond-Gignac, France

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.20</td>
<td>MBGE</td>
<td>Effects of Inhibition of Wnt/beta-catenin Pathway on Amacrine and Muller cells in Retinas of Zebrafish Embryos at Different Development Stages</td>
<td>Ayse İpek Akyuz Unsal, Turkey</td>
</tr>
<tr>
<td>16.25</td>
<td>NSPH</td>
<td>Retinal Neurodegeneration And Neuroinflammation In A Sod1 Mouse Model Of Als</td>
<td>María Pilar Rojas Lozano, Spain</td>
</tr>
<tr>
<td>16.30</td>
<td>PO</td>
<td>Radiological work-up for proton beam therapy of uveal melanoma patients</td>
<td>Myriam Jaarsma-Coes, Netherlands</td>
</tr>
<tr>
<td>16.35</td>
<td>PBV</td>
<td>Decreased docosahexaenoic acid and other specific fatty acids in a mouse model of retinal degeneration</td>
<td>María José Ruiz Pastor, Spain</td>
</tr>
<tr>
<td>16.40</td>
<td>RV</td>
<td>Identification of eleven differentially expressed proteins in the tear film of patients with neovascular Age-related Macular Degeneration (AMD)</td>
<td>Mateusz Winiarczyk, Poland</td>
</tr>
<tr>
<td>16.45</td>
<td></td>
<td><strong>LIVE Q &amp; A</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Awards

17.00 - 17.10

### General Assembly

17.10 - 17.40
INDUSTRY WEBINAR - 27 SEPTEMBER

21.00-22.00

Learning from the learners

Moderators: Harminder Dua, United Kingdom,
            Miriam Kolko, Denmark,
            João Barbosa Breda, Portugal

Management of glaucoma patients in 2021
Anthony Khawaja, United Kingdom

Dry eye treat it as a disease
Antoine Rousseau, France

Cornea Surgery Technics
Giuseppe Giannaccare, Italy

Tricks in complicated Cataract Surgery
Panagiotis Salvanos, Greece

Tips for Retina surgery
Jelena Potic, Switzerland

Discussion
INDUSTRY SYMPOSIA - 2 October

12.15-13.00

How to treat evaporative dry eye associated with MGD in clinical practice?

Moderator: Kostas Boboridis, Greece

Pathophysiology of evaporative dry eye associated with MGD
Kostas Boboridis, Greece

Treatment schemes for evaporative dry eye relief
Elisabeth Messmer, Germany

Refractory MGD - Is it Demodex?
Teifi James, United Kingdom

13.00-13.45

New perspectives in LHON management

Moderator: Letizia Gabaglio, Italy

Speakers: Thomas Klopstock, Germany
Berthold Pemp, Austria

ON DEMAND INDUSTRY SYMPOSIUM

Mechanisms of Action: Steroids & Anti VEGF's, how do they really work?

Moderator: Francine Behar-Cohen, France
Acknowledgements

EVER wishes to express its gratitude to all Sponsors for their generous support to the Congress

MAJOR SPONSORS

Chiesi

Théa

let’s open our eyes

SPONSORS

Allergan

an AbbVie company

Horus PHARMA

SOLUTION MAKERS

LHON is a rare eye condition that causes the loss of central vision, generally in both eyes, and can lead to blindness. As vision is lost, activities such as reading, driving and recognising faces become increasingly difficult. 1,2

LHON is commonly misdiagnosed as other more common optic neuropathies, delaying treatment initiation. 3,4

Diagnose early and help light up their future

With undiagnosed LHON, the future looks dark

Théa is a profoundly European company whose independence, stability and entrepreneurial spirit are safeguarded by the Chibret family, which has been instrumental in the field of ophthalmology for over 150 years. This family governance model focuses on Théa, its employees, people values and long-term development to fulfill our mission: to be the “Ophthalmology Specialist”.

Pioneer in preservative-free eye care treatments, our commitment is to provide innovative products and a wide range of medicinal products (service products, daily-use products) to healthcare providers and patients in all ophthalmological therapeutic classes.

We constantly reinvest in Théa’s two priority areas of Innovation and Internationalisation, with long-term strategy outweighing short-term profit. Our objectives are continuity, enhancing long-term partnerships and collaborative research, transmitting our knowledge, tackling unmet medical needs by offering new treatment or patient support models.

Internationalisation is rooted in our genes: Théa is currently the first independent ophthalmology laboratory in Europe, and aims to become a world leader in terms of export and international presence in compliance with the culture of each country where it is present.

It is this vision that makes Théa unique.